Table 3.

Clinicopathological factors investigated for overall survival and progression-free survival.

Characteristic	Overall survival			Progression-free survival
	HR	95% CI	p-value	HR	95% CI	p-value
B-symptoms (Present vs Absent)	3.89	1.64–9.22	0.0020	1.90	0.92–3.90	0.0808
ECOG performance status (1–4 vs 0)	1.80	0.85–3.82	0.1234	1.83	0.96–3.50	0.0671
Stage (3–4 vs 1–2)	3.53	1.67–7.47	0.0010	2.66	1.40–5.06	0.0028
Grade (3 vs 1–2)	0.48	0.20–1.12	0.0890	0.51	0.24–1.07	0.0744
No. of lymph node involvement (≥4 vs 1–3)	2.75	1.08–7.00	0.0337	3.21	1.42–7.24	0.0050
Response to chemotherapy (Non-CR vs CR)	18.17	7.40–44.64	<0.0001	10.88	4.89–24.23	<0.0001
Chemotherapy regimen (Others vs R-CHOP)	6.86	2.18–21.58	0.0010	2.98	1.12–7.94	0.0287
BCL2 expression (Positive vs Negative)	1.29	0.55–3.02	0.5529	1.81	0.87–3.76	0.1146
BCL6 expression (Positive vs Negative)	0.69	0.13–3.63	0.6584	0.55	0.13–2.38	0.4275
CD10 expression (Positive vs Negative)	0.83	0.36–1.90	0.6537	1.05	0.51–2.17	0.8916
MUM1 expression (Positive vs Negative)	1.76	0.75–4.13	0.1958	1.86	0.88–3.96	0.1061
KI-67 expression (≥90% vs < 90%)	1.06	0.41–2.77	0.9053	0.59	0.28–1.27	0.1801
MYC expression (≥40% vs < 40%)	0.63	0.20–1.96	0.4267	0.98	0.34–2.83	0.9757
Cell of origin (ABC vs GCB)	1.80	0.84–3.86	0.1330	1.71	0.88–3.32	0.1105
BCL2 rearrangement (Positive vs Negative/unknown)	2.04	0.78–5.36	0.1488	2.18	0.91–5.22	0.0788
BCL6 rearrangement (Positive vs Negative/unknown)	2.60	0.94–7.17	0.0653	2.00	0.82–4.90	0.1275
MYC rearrangement (Positive vs Negative/unknown)	4.37	0.72–26.40	0.1077	2.18	0.47–10.05	0.3193
BCL6 and/or MYC rearrangement (Negative/unknown)	3.24	1.29–8.14	0.0125	2.18	0.97–4.87	0.0581

Abbreviations: ECOG, Eastern Cooperative Oncology Group.